Zevra Therapeutics (ZVRA) Debt to Equity (2020 - 2025)
Historic Debt to Equity for Zevra Therapeutics (ZVRA) over the last 8 years, with Q3 2025 value amounting to $0.46.
- Zevra Therapeutics' Debt to Equity fell 4546.63% to $0.46 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.46, marking a year-over-year decrease of 4546.63%. This contributed to the annual value of $1.5 for FY2024, which is 11700.37% up from last year.
- Latest data reveals that Zevra Therapeutics reported Debt to Equity of $0.46 as of Q3 2025, which was down 4546.63% from $0.52 recorded in Q2 2025.
- In the past 5 years, Zevra Therapeutics' Debt to Equity registered a high of $1.8 during Q2 2024, and its lowest value of $0.01 during Q1 2021.
- Moreover, its 5-year median value for Debt to Equity was $0.52 (2025), whereas its average is $0.6.
- As far as peak fluctuations go, Zevra Therapeutics' Debt to Equity skyrocketed by 611199.57% in 2024, and later plummeted by 7117.26% in 2025.
- Quarter analysis of 5 years shows Zevra Therapeutics' Debt to Equity stood at $0.01 in 2021, then soared by 1738.14% to $0.17 in 2022, then skyrocketed by 305.7% to $0.69 in 2023, then skyrocketed by 117.0% to $1.5 in 2024, then crashed by 69.31% to $0.46 in 2025.
- Its Debt to Equity stands at $0.46 for Q3 2025, versus $0.52 for Q2 2025 and $1.46 for Q1 2025.